GNRX
VanEck Vectors Generic Drugs ETF
GNRX
GNRX
Delisted
GNRX was delisted on the 4th of April, 2019.
3 hedge funds and large institutions have $414K invested in VanEck Vectors Generic Drugs ETF in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
3
Holders Change
+2
Holders Change %
+200%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$257K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$15K |
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $257K | +$257K | +11,614 | New |
|
|
APA
2
American Portfolios Advisors
Holbrook,
New York
| $142K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $15K | +$15K | +660 | New |
|